SomnoMed Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SOM.AX research report →
Price Chart
About the company
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances.
- CEO
- Karen Borg
- IPO
- 2004
- Employees
- 300
- HQ
- Crows Nest, NSW, AU
Get TickerSpark's AI analysis on SOM.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.02M
- P/E
- -29.34
- Fwd P/E
- 17.75
- PEG
- -0.26
- P/S
- 0.66
- P/B
- 1.54
- EV/EBITDA
- 17.72
- Div Yield
- 0.00%
- Gross Margin
- 57.40%
- Op Margin
- 2.35%
- Net Margin
- -2.16%
- ROE
- -5.31%
- ROIC
- 4.55%
Latest fiscal year · YoY change
- Revenue
- $111.49M+21.6%
- Gross Profit
- $66.73M+21.0%
- Op Income
- $3.62M
- Net Income
- $-3,456,329+71.8%
- EPS
- $-0.02+83.7%
- OCF Growth
- +222.9%
- FCF Growth
- +169.5%
- 52W High
- $0.94
- 52W Low
- $0.33
- 50D MA
- $0.47
- 200D MA
- $0.62
- Beta
- 0.80
- RSI (14)
- 33
- Avg Volume
- 127.87K
No earnings-call transcripts are available for SOM.AX yet.
- Free Float
- 77.1%
- Shares Outstanding
- 219.77M
- Float Shares
- 169.41M
Our SOM.AX coverage
Recent articles, reports, and earnings notes.
No research on SOM.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SOM.AX report →